IRulya Therapeutics Inc
quincetx.comWhat Do They Do?
Evaluates strategic alternatives, including a possible reverse merger, while preserving cash.
10-K for FY2025, filed Apr 10, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$75.5MView ↗
- ▲ +370% (Loss)
- vs −$16M in Q2 FY2025
-
Sep 8, 2026
Sold AIDE and eDSP assets and its Italian subsidiary
Ayma paid $450,000 in cash.
Sources
8-K, filed Sep 14, 2026
On September 8, 2026, Quince Therapeutics, Inc. (the “Company”) completed the sale of (i) all of the issued and outstanding equity…View ↗
-
Jul 31, 2026
Announced conditional CEO departure and successor appointment
Dirk Thye's resignation and Brigette Roberts's CEO appointment depend on stockholder approval of proposals.
Sources
8-K, filed Jul 31, 2026
On July 29, 2026, each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “Company”)…View ↗
-
May 18, 2026
Acquired Orphai, adding LAM-001 to its pulmonary drug pipeline
LAM-001 is an inhaled rapamycin treatment in development for pulmonary diseases including PH-ILD and BOS.
Sources
8-K, filed May 18, 2026
South San Francisco, CA, May 18, 2026 – Quince Therapeutics, Inc. (Nasdaq: QNCX) announced it has acquired Orphai Therapeutics Inc., a…View ↗
From bone therapies to AIDE
The earlier report focused on a bone-targeting drug platform for skeletal diseases and fractures; the latest described AIDE drug delivery and eDSP for a rare pediatric neurodegenerative disease, then said development would stop and strategic alternatives would become the focus.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Apr 10, 2026We are a preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare…View ↗
NOV004 was discovered using our broad drug-targeting platform designed to precisely deliver small molecules, peptides, or large molecules…View ↗
Our discovery pipeline is potentially applicable across multiple skeletal therapeutic indications to address underserved therapeutic areas…View ↗
Loading...
